The oral iron chelator deferiprone has been shown to be more effective at reducing myocardial iron load than subcutaneous desferrioxamine. The clinical benefit was significantly improved ventricular function in the deferiprone group.

Ref:

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia (2002). Lisa J Anderson, Beatrix Wonke, Emma Prescott, Sally Holden, J Malcolm Walker, Dudley J Pennell. Lancet 2002; 360: 516-20